StockNews.com Begins Coverage of Tonix Pharmaceuticals

StockNews.com has recently initiated coverage on Tonix Pharmaceuticals Holding Corp. TNXP, a biopharmaceutical company with its headquarters in Chatham, New Jersey. In their opening analysis, StockNews.com has given the stock a "sell" rating. This evaluation follows an earlier adjustment by Alliance Global Partners, who lowered their price target for Tonix Pharmaceuticals from $18.00 to $8.00 yet maintained a "buy" rating for the company.

Financial Performance and Stock Evaluation

The commencement of the trading session on Thursday saw TNXP shares opening at $0.47. Within the span of the past 12 months, the stock has experienced a low of $0.43 and a peak of $9.81. The company's stock price is influenced by several indicators, including a fifty-day simple moving average of $0.66 and a 200-day simple moving average of $1.40. With a market capitalization standing at approximately $8.33 million, a price-to-earnings (PE) ratio of -0.03, and a beta of 2.44, the financial health of the company can be gauged through these metrics.

During the last reporting of its quarterly earnings on August 10th, Tonix Pharmaceuticals announced a loss per share (EPS) of ($2.68), which surpassed the consensus estimate of a ($2.78) loss per share. Analysts predict that for the current fiscal year, the company will post an earnings loss of $-7.74 per share.

Institutional Investors' Activity

There has been a varied level of engagement from institutional investors and hedge funds in Tonix Pharmaceuticals. Notably, UBS Group AG UBS enhanced its stake by 18,868.5% in the 4th quarter, acquiring 67,528 shares valued at about $26,000. Another major player, Two Sigma Investments LP, increased ownership by 183.9%, holding 60,191 shares worth $36,000. JPMorgan Chase & Co. JPM augmented their holdings by 36.9%, now owning 285,321 shares valued at $66,000. Furthermore, Virtu Financial LLC VIRT amplified their position by 44.8%, holding 188,075 shares with a value of $73,000. Collectively, institutional investors and hedge funds own about 5.76% of the company's stock.

The Company's Market Focus

Tonix Pharmaceuticals primarily zeroes in on the development, licensing, and commercialization of therapeutics aimed at treating human diseases and easing the suffering associated with them. Presently, the company markets Zembrace SymTouch and Tosymra, both of which are utilized for acute migraine treatment, either with or without aura, in adults.

StockNews, TNXP, Coverage